These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37797284)

  • 21. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
    Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: A retrospective multicenter study.
    Perry C; Ben Barouch S; Goldschmidt N; Sarid N; Herishanu Y; Shvidel L; Bairey O; Lavi N; Horowitz N; Avigdor A; Lebel E; Sofer O; Ram R; Avivi I
    Am J Hematol; 2019 Sep; 94(9):992-1001. PubMed ID: 31211434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma.
    Faqah A; Asif S; Goksu SY; Sheikh HS
    JCO Glob Oncol; 2021 Apr; 7():486-494. PubMed ID: 33835825
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma.
    Cheah CY; Herbert KE; O'Rourke K; Kennedy GA; George A; Fedele PL; Gilbertson M; Tan SY; Ritchie DS; Opat SS; Prince HM; Dickinson M; Burbury K; Wolf M; Januszewicz EH; Tam CS; Westerman DA; Carney DA; Harrison SJ; Seymour JF
    Br J Cancer; 2014 Sep; 111(6):1072-9. PubMed ID: 25072255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab.
    Estephan F; Ye X; Dzaye O; Wagner-Johnston N; Swinnen L; Gladstone DE; Ambinder R; Kamson DO; Lambrecht S; Grossman SA; Lin DDM; Holdhoff M
    J Neurooncol; 2019 Dec; 145(3):461-466. PubMed ID: 31621040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma.
    Kim H; Jeong H; Yamaguchi M; Sohn I; Yoon SE; Byeon S; Hur JY; Koh Y; Yoon SS; Kim EJ; Oguchi M; Miyazaki K; Taguchi S; Yoon DH; Cho J; Ko YH; Kim SJ; Suzuki R; Kim WS
    Blood; 2020 Nov; 136(22):2548-2556. PubMed ID: 32584959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of Key Factors Associated with Response to Salvage High-Dose Methotrexate Rechallenge in Primary Central Nervous System Lymphoma with First Relapse.
    Du P; Chen H; Shen L; Liu X; Wu X; Chen L; Cao A; Geng D
    Curr Oncol; 2022 Sep; 29(9):6642-6656. PubMed ID: 36135091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients.
    Sarid N; Bokstein F; Blumenthal DT; Weiss-Meilik A; Gibstein L; Avivi I; Perry C; Ram R
    J Neurooncol; 2021 Jan; 151(2):211-220. PubMed ID: 33099747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose methotrexate monotherapy for newly diagnosed primary central nervous system lymphoma: 15-year multicenter experience.
    Yoon WS; Park JS; Kim YI; Chung DS; Jeun SS; Hong YK; Yang SH
    Asia Pac J Clin Oncol; 2021 Feb; 17(1):123-130. PubMed ID: 32978898
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
    Arkenau HT; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
    Ann Oncol; 2007 Mar; 18(3):541-5. PubMed ID: 17164228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
    Zhong K; Shi Y; Gao Y; Zhang H; Zhang M; Zhang Q; Cen X; Xue M; Qin Y; Zhao Y; Zhang L; Liang R; Wang N; Xie Y; Yang Y; Liu A; Bao H; Wang J; Cao B; Zhang W; Zhang W
    BMC Cancer; 2023 Aug; 23(1):746. PubMed ID: 37568079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
    Han X; Ji Y; Ouyang M; Zhu T; Zhou D
    Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single-center real-world clinical experience.
    Min GJ; Kim TY; Jeon YW; O JH; Choi BO; Park G; Park YH; Cho SG
    Cancer Med; 2023 Apr; 12(7):7911-7922. PubMed ID: 36721307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial.
    Joerger M; Huitema AD; Krähenbühl S; Schellens JH; Cerny T; Reni M; Zucca E; Cavalli F; Ferreri AJ
    Br J Cancer; 2010 Feb; 102(4):673-7. PubMed ID: 20125159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials.
    Yu J; Du H; Ye X; Zhang L; Xiao H
    Sci Rep; 2021 Jan; 11(1):2125. PubMed ID: 33483528
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
    Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
    Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
    Bokstein F; Lossos A; Lossos IS; Siegal T
    Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrathecal methotrexate prophylaxis and central nervous system relapse in patients with diffuse large B-cell lymphoma following rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
    Tomita N; Takasaki H; Ishiyama Y; Kishimoto K; Ishibashi D; Koyama S; Ishii Y; Takahashi H; Numata A; Watanabe R; Tachibana T; Ohshima R; Hagihara M; Hashimoto C; Takemura S; Taguchi J; Fujimaki K; Sakai R; Motomura S; Ishigatsubo Y
    Leuk Lymphoma; 2015 Mar; 56(3):725-9. PubMed ID: 24913502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited efficacy of high-dose methotrexate to prevent the central nervous system relapse in patients with IVLBCL.
    Terao T; Tsushima T; Ikeda D; Fukumoto A; Kamura Y; Kuzume A; Tabata R; Miura D; Narita K; Takeuchi M; Matsue K
    Leuk Lymphoma; 2022 Dec; 63(14):3394-3401. PubMed ID: 36111741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.